Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodo...

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonald, Lisa D., MacKay, Alecia, Kaliaperumal, Valarmathy, Weir, Genevieve, Penwell, Andrea, Rajagopalan, Rajkannan, Langley, Joanne M., Halperin, Scott, Mansour, Marc, Stanford, Marianne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791585/
https://www.ncbi.nlm.nih.gov/pubmed/28933663
http://dx.doi.org/10.1080/21645515.2017.1375637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791585/
https://www.ncbi.nlm.nih.gov/pubmed/28933663
http://dx.doi.org/10.1080/21645515.2017.1375637

Ejemplares similares